Search

Your search keyword '"Marquez-Rodas, I."' showing total 178 results
Start Over Author "Marquez-Rodas, I."
178 results on '"Marquez-Rodas, I."'

1. An update on access to novel treatment for metastatic melanoma in Europe — A 2024 survey of the European melanoma registry and the European association of dermato-oncology

Author

Kandolf, L., Ascierto, P.A., Bastholt, L., Gavrilova, I., Haanen, J., Hauschild, A., Herceg, D., Hoeller, C., Jalovcic Suljevic, A., Kessels, JI, Krajsova, I., Kukushkina, M., Lallas, A., Lorigan, P., Mangana, J., Marquez-Rodas, I., Mazilu, L., Mohr, P., Bylaite-Bucinskiene, M., Ocvirk, J., Olah, J., Putnik, K., Rutkowski, P., Saiag, P., Samolyenko, I., Schwarze, J.K., Stojkovski, I., Cicmil Sarić, N., Vieira, R., Weichenthal, M., and Garbe, C.

Published
2025
Full Text
View/download PDF

2. Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients

Author

Robert, C., Long, G.V., Larkin, J., Wolchok, J.D., Hassel, J.C., Schadendorf, D., Hodi, F.S., Lebbé, C., Grob, J.-J., Hyngstrom, J.R., Wagstaff, J., Chesney, J., Butler, M.O., Bechter, O., Márquez-Rodas, I., Pavlick, A.C., Durani, P., Pe Benito, M., Wang, P., Postow, M.A., and Ascierto, P.A.

Published
2025
Full Text
View/download PDF

3. Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV melanoma: a multicenter international study

Author

Chatziioannou, E., Higuita, L.M. Serna, Kreft, S., Kandolf, L., Dujovic, B., Reinhardt, L., Tamara, E., Marquez-Rodas, I., Fortuna, A.R.F.P., Nübling, A., Niessner, H., Forschner, A., Garbe, C., Popovic, A., Mirjana, B., Meier, F., Eigentler, T., Leiter, U., Flatz, L., Sinnberg, T., and Amaral, T.

Published
2024
Full Text
View/download PDF

4. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee

Author

Keilholz, U., Ascierto, P.A., Dummer, R., Robert, C., Lorigan, P., van Akkooi, A., Arance, A., Blank, C.U., Chiarion Sileni, V., Donia, M., Faries, M.B., Gaudy-Marqueste, C., Gogas, H., Grob, J.J., Guckenberger, M., Haanen, J., Hayes, A.J., Hoeller, C., Lebbé, C., Lugowska, I., Mandalà, M., Márquez-Rodas, I., Nathan, P., Neyns, B., Olofsson Bagge, R., Puig, S., Rutkowski, P., Schilling, B., Sondak, V.K., Tawbi, H., Testori, A., and Michielin, O.

Published
2020
Full Text
View/download PDF

5. ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee

Author

Michielin, O., van Akkooi, A., Lorigan, P., Ascierto, P.A., Dummer, R., Robert, C., Arance, A., Blank, C.U., Chiarion Sileni, V., Donia, M., Faries, M.B., Gaudy-Marqueste, C., Gogas, H., Grob, J.J., Guckenberger, M., Haanen, J., Hayes, A.J., Hoeller, C., Lebbé, C., Lugowska, I., Mandalà, M., Márquez-Rodas, I., Nathan, P., Neyns, B., Olofsson Bagge, R., Puig, S., Rutkowski, P., Schilling, B., Sondak, V.K., Tawbi, H., Testori, A., and Keilholz, U.

Published
2020
Full Text
View/download PDF

8. Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program

Author

González-Cao, M., Arance, A., Piulats, J. M., Marquez-Rodas, I., Manzano, J. L., Berrocal, A., Crespo, G., Rodriguez, D., Perez-Ruiz, E., Berciano, M., Soria, A., Castano, A. G., Espinosa, E., Montagut, C., Alonso, L., Puertolas, T., Aguado, C., Royo, M. A., Blanco, R., Rodríguez, J. F., Muñoz, E., Mut, P., Barron, F., Martin-Algarra, S., and Spanish Melanoma Group

Published
2017
Full Text
View/download PDF

10. 848P Second-line systemic treatment for patients with advanced melanoma: Results from the prospective real-world study GEM1801

Author

Marquez-Rodas, I., primary, Berciano Guerrero, M.A., additional, Muñoz Couselo, E., additional, Soria, A., additional, Cerezuela-Fuentes, P., additional, Manzano Mozo, J.L., additional, Gutierrez Sanz, L., additional, Crespo, G., additional, Puértolas, T., additional, Garcia Castano, A., additional, Aguado de la Rosa, C., additional, Espinosa, E., additional, Majem Tarruella, M., additional, López Castro, R., additional, Ayala de Miguel, P., additional, Medina Martinez, J., additional, Fernández Morales, L.A., additional, Bellido Hernández, L., additional, Berrocal, A., additional, and Martín Algarra, S., additional

Published
2022
Full Text
View/download PDF

11. 826P Encorafenib and binimetinib followed by radiotherapy for patients with symptomatic BRAF mutated melanoma brain metastases: GEM1802/E-BRAIN clinical trial

Author

Marquez-Rodas, I., primary, Arance Fernandez, A.M., additional, Berciano Guerrero, M.A., additional, Garcia Castano, A., additional, Alamo De La Gala, M.D.C., additional, Gonzalez Cao, M., additional, Sanchez Mauriño, P., additional, Diaz Beveridge, R.P., additional, Valduvieco, I., additional, Delgado, R., additional, Prada, P.J., additional, Puertas, E., additional, Romero, J.L., additional, Conde, A., additional, Alvarez, A., additional, and Berrocal, A., additional

Published
2022
Full Text
View/download PDF

15. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

Author

Wolchok, JD, Chiarion-Sileni, V, Gonzalez, R, Grob, J-J, Rutkowski, P, Lao, CD, Cowey, CL, Schadendorf, D, Wagstaff, J, Dummer, R, Ferrucci, PF, Smylie, M, Butler, MO, Hill, A, Marquez-Rodas, I, Haanen, JBAG, Guidoboni, M, Maio, M, Schoffski, P, Carlino, MS, Lebbe, C, McArthur, G, Ascierto, PA, Daniels, GA, Long, G, Bas, T, Ritchings, C, Larkin, J, Hodi, FS, Wolchok, JD, Chiarion-Sileni, V, Gonzalez, R, Grob, J-J, Rutkowski, P, Lao, CD, Cowey, CL, Schadendorf, D, Wagstaff, J, Dummer, R, Ferrucci, PF, Smylie, M, Butler, MO, Hill, A, Marquez-Rodas, I, Haanen, JBAG, Guidoboni, M, Maio, M, Schoffski, P, Carlino, MS, Lebbe, C, McArthur, G, Ascierto, PA, Daniels, GA, Long, G, Bas, T, Ritchings, C, Larkin, J, and Hodi, FS

Abstract

PURPOSE: In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolumab alone versus ipilimumab. Here, we report 6.5-year efficacy and safety outcomes. PATIENTS AND METHODS: Patients with previously untreated unresectable stage III or stage IV melanoma were randomly assigned 1:1:1 to receive nivolumab 1 mg/kg plus ipilimumab 3 mg/kg once every 3 weeks (four doses) followed by nivolumab 3 mg/kg once every 2 weeks (n = 314), nivolumab 3 mg/kg once every 2 weeks (n = 316), or ipilimumab 3 mg/kg once every 3 weeks (four doses; n = 315). Coprimary end points were progression-free survival and overall survival (OS) with nivolumab plus ipilimumab or nivolumab versus ipilimumab. Secondary end points included objective response rate, descriptive efficacy assessments of nivolumab plus ipilimumab versus nivolumab alone, and safety. Melanoma-specific survival (MSS; descriptive analysis), which excludes deaths unrelated to melanoma, was also evaluated. RESULTS: Median OS (minimum follow-up, 6.5 years) was 72.1, 36.9, and 19.9 months in the combination, nivolumab, and ipilimumab groups, respectively. Median MSS was not reached, 58.7, and 21.9 months, respectively; 6.5-year OS rates were 57%, 43%, and 25% in patients with BRAF-mutant tumors and 46%, 42%, and 22% in those with BRAF-wild-type tumors, respectively. In patients who discontinued treatment, the median treatment-free interval was 27.6, 2.3, and 1.9 months, respectively. Since the 5-year analysis, no new safety signals were observed. CONCLUSION: These 6.5-year CheckMate 067 results, which include the longest median OS in a phase III melanoma trial reported to date and the first report of MSS, showed durable, improved clinical outcomes with nivolumab plus ipilimumab or nivolumab versus ipilimumab in patients with advanced melanoma and, in descriptive analyses, with the combination over nivolumab monotherapy.

Published
2022

16. 85P Correlation between nCOUNTER PAM-50 assay and three IHC-based surrogate intrinsic breast cancer subtype classifiers: A real-world study

Author

Martín, M., primary, Del Monte-Millán, M., additional, Jerez, Y., additional, Echavarria Diaz-Guardamino, I., additional, Herrero Lopez, B., additional, Gamez Casado, S., additional, Roche-Molina, M., additional, Marquez-Rodas, I., additional, Cebollero, M., additional, Alvarez, E., additional, Massarrah, T., additional, Ocaña, I., additional, Arias, A., additional, García Saenz, J.Á., additional, Moreno Anton, F., additional, Olier Garate, C., additional, Moreno Muñoz, D., additional, Marrupe Gonzalez, D., additional, Merina, T., additional, and Lopez-Tarruella Cobo, S., additional

Published
2022
Full Text
View/download PDF

19. 1038MO Intracranial activity of encorafenib and binimetinib followed by radiotherapy in patients with BRAF mutated melanoma and brain metastasis: Preliminary results of the GEM1802/EBRAIN-MEL phase II clinical trial

Author

Marquez-Rodas, I., primary, Arance, A., additional, Berciano Guerrero, M.A., additional, Díaz Beveridge, R., additional, Alamo, M.D.C., additional, Garcia Castaño, A., additional, Gonzalez Cao, M., additional, Vidal, J., additional, Puertolas Hernandez, T., additional, Soria, A., additional, Aguado de la Rosa, C., additional, Sánchez Mauriño, P., additional, Valduvieco, I., additional, Delgado Rico, R., additional, Conde, A., additional, Foro, P., additional, Prada, P.J., additional, Puertas, E., additional, Alvarez Gonzalez, A., additional, and Berrocal, A., additional

Published
2021
Full Text
View/download PDF

20. 1056P Survival of patients with advanced melanoma according to first-line treatment and key prognostic factors: Real-world data from GEM1801 study

Author

Marquez-Rodas, I., primary, Berciano Guerrero, M.A., additional, Muñoz Couselo, E., additional, Manzano, J.L., additional, Crespo Herrero, G., additional, Soria, A., additional, Cerezuela, P., additional, Puertolas Hernandez, T., additional, Berrocal, A., additional, Majem Tarruella, M., additional, Bellido Hernández, L., additional, Espinosa, E., additional, Garcia Castano, A., additional, Medina Martínez, J., additional, Fernandez Morales, L.A., additional, Aguado de la Rosa, C., additional, Gutierrez Sanz, L., additional, Lopez Castro, R., additional, Ayala de Miguel, P., additional, and Martin Algarra, S., additional

Published
2021
Full Text
View/download PDF

23. 1174P Sex differences in advanced melanoma in Spain: Results from the prospective real-world study GEM 1801

Author

Muñoz Couselo, E., Berciano-Guerrero, M-Á., Manzano, J.L., Soria, A., Cerezuela-Fuentes, P., Crespo, G., Antoñanzas, M., Puértolas, T., García Castaño, A., Gutiérrez Sanz, L., Espinosa, E., Ayala de Miguel, P., Majem, M., López Castro, R., Fernández-Morales, L.A., Rivas, B., Medina, J., Berrocal, A., Martín Algarra, S., and Márquez-Rodas, I.

Published
2023
Full Text
View/download PDF

24. 233P Germline genetic testing before formal counseling: Impact in cancer management in a Spanish university hospital

Author

Bringas Beranek, M., Echavarria Diaz-Guardamino, I., Polo, C., Flores Sanchez, C., Munoz Martin, A.J., Ortega Morán, L., Herrero Lopez, B., Calvo Ferrandiz, P.A., Jerez Gilarranz, Y., Torres Perez-Solero, G., Lopez-Tarruella Cobo, S., Gamez Casado, S., Perez Ramirez, S., Veiga Fernández, A., Pajares, J.A., Sanz, M., Suarez, J., Del Monte-Millan, M., Martin Jimenez, M., and Marquez-Rodas, I.

Published
2023
Full Text
View/download PDF

25. 1159P Characterization of melanoma of unknown primary in the era of immunotherapy and targeted therapy in Spain: Results from the prospective real-world study GEM 1801

Author

Cerezuela-Fuentes, P., Piñero-Madrona, A., Muñoz-Couselo, E., Manzano, J.L., Berciano-Guerrero, M-Á., Majem, M., Espinosa, E., Soria, A., Ayala de Miguel, P., García Castaño, A., Crespo, G., Gutiérrez Sanz, L., Aguado de la Rosa, C., Fernández-Morales, L.A., Puértolas, T., Fra, J., Rodríguez de la Borbolla, M., Bellido, L., Martín Algarra, S., and Márquez-Rodas, I.

Published
2023
Full Text
View/download PDF

27. SEOM clinical guideline for the management of cutaneous melanoma (2020)

Author

Universidad de Sevilla. Departamento de Medicina, Majem, M., Manzano, J. L., Marquez-Rodas, I., Mujika, K., Muñoz-Couselo, E., Pérez-Ruiz, E., Cruz Merino, Luis de la, Espinosa, E., Gonzalez-Cao, M., Berrocal, A., Universidad de Sevilla. Departamento de Medicina, Majem, M., Manzano, J. L., Marquez-Rodas, I., Mujika, K., Muñoz-Couselo, E., Pérez-Ruiz, E., Cruz Merino, Luis de la, Espinosa, E., Gonzalez-Cao, M., and Berrocal, A.

Abstract

Melanoma afects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and determination of BRAF status has to be performed in patients with stage≥III. Stage I–III resectable melanomas will be treated surgically. In patients with stage III melanoma, adjuvant treatment with immuno‑ therapy or targeted therapy is also recommended. Patients with unresectable or metastatic melanoma will receive treatment with immunotherapy or targeted therapy, the optimal sequence of these treatments remains unclear. Brain metastases require a separate consideration, since, in addition to systemic treatment, they may require local treatment. Patients must be followed up closely to receive or change treatment as soon as their previous clinical condition changes, since multiple therapeutic options are available.

Published
2021

28. PO-1557 RT after Encorafenib and Binimetinib on BRAF mutated melanoma brain metastases. GEM1802-Phase II

Author

Alvarez, A., Valduvieco, I., Arance, A., Delgado, R., Berciano, M.A., López Campos, F., Soria, A., Romero, J.L., Sánchez Mauriño, P., Lucas, A., Martín Liberal, J., Prada, P.J., García Castaño, A., Alamo, M.C., Puertas, E., González Cao, M., Conde, A., Díaz Beveridge, R., Corona, J.A., Aguado, C., Foro, P., Vidal, J., López Soler, F., Cerezuela Fuentes, P., and Márquez Rodas, I.

Published
2023
Full Text
View/download PDF

29. LBA66_PR Disparities in access to oncology clinical trials in Europe in the period 2009-2019

Author

Carneiro, A., primary, Amaral, T.M.S., additional, Brandao, M., additional, Scheffler, M., additional, Bol, K., additional, Ferrara, R., additional, Jalving, M., additional, Lo Russo, G., additional, Marquez-Rodas, I., additional, Matikas, A., additional, Mezquita, L., additional, Morgan, G., additional, Onesti, C.E., additional, Pilotto, S., additional, Saloustros, E., additional, and Trapani, D., additional

Published
2020
Full Text
View/download PDF

30. COVID-19 in melanoma patients: Spanish register

Author

Gonzalez-Cao, M, Carrera, C, Moreno, JFR, Rodriguez-Jimenez, P, Basa, MA, Rodriguez, MF, Puertolas, T, Munoz, E, Manzano, JL, Marquez-Rodas, I, Martin-Liberal, J, Soria, A, Criado, PL, Castano, AG, Boada, A, de Miguel, PA, Puig, S, Crespo, G, Fra, PL, Zamora, CA, Gardeazabal, J, Seral, CM, Drozdowskyj, A, Provencio, M, and Berrocal, A

Published
2020

33. EP08.01-048 Spanish Immunotherapy Registry of Cardiovascular Toxicity (SIR-CVT): Preliminary Analysis of the Lung Cancer Cohort

Author

Gutiérrez Sainz, L., Cruz Castellanos, P., Higuera Gómez, O., López Fernández, T., Terol Espinosa de los Monteros, B., Valbuena López, S., Buño, A., Cuesta, E., Del Barco, E., Terán Brage, E., Martín García, A., Eiros Bachiller, R., Sánchez Pablo, C., Martínez Banaclocha, N., Lozano, T., Márquez Rodas, I., Pérez Ramírez, S., Calles Blanco, A., Álvarez, R., Zatarain Nicolás, E., De la Haba Rodríguez, J., Sánchez Mauriño, P., Mesa Rubio, D., Esteban Martínez, F., Martín Fernández, P., Ibáñez Cabeza, B., and De Castro Carpeño, J.

Published
2022
Full Text
View/download PDF

34. Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)

Author

Schadendorf, D. Ascierto, P.A. Haanen, J. Espinosa, E. Demidov, L. Garbe, C. Guida, M. Lorigan, P. Chiarion-Sileni, V. Gogas, H. Maio, M. Fierro, M.T. Hoeller, C. Terheyden, P. Gutzmer, R. Guren, T.K. Bafaloukos, D. Rutkowski, P. Plummer, R. Waterston, A. Kaatz, M. Mandala, M. Marquez-Rodas, I. Muñoz-Couselo, E. Dummer, R. Grigoryeva, E. Young, T.C. Nathan, P.

Abstract

Background: Limited data are available on nivolumab in challenging subgroups with advanced melanoma. We report outcomes of nivolumab after prior ipilimumab in patients who are typically excluded from clinical trials. Patients and methods: In this phase II, single-arm, open-label, multicentre study (CheckMate 172), patients with advanced melanoma who progressed on or after ipilimumab received nivolumab 3 mg/kg, every 2 weeks for up to 2 years. The primary objective was incidence of grade ≥3, treatment-related select adverse events (AEs). Results: At a minimum follow-up of 18 months, grade ≥3 treatment-related select AEs with the most variation across subgroups were diarrhoea and colitis (1.1% [n = 11] and 0.3% [n = 3] for the total population [n = 1008]; 0.6% [n = 1] and 0.6% [n = 1] for patients with an asymptomatic central nervous system [CNS] metastasis [n = 165; 16.4%]; 4.5% [n = 3] and 3.0% [n = 2] for patients with an Eastern Cooperative Oncology Group performance status [ECOG PS] of 2 [n = 66; 6.5%]; 2.4% [n = 2] and 0% for those who experienced a grade 3/4 immune-related AE [irAE] with prior ipilimumab [n = 84; 8.3%]; and 0% and 0% for autoimmune disease [n = 25; 2.5%], respectively). Median overall survival was 21.4 months in the total population and was 11.6, 2.4, 21.5, and 18.6 months in patients with a CNS metastasis, ECOG PS 2, a grade 3/4 irAE with prior ipilimumab, and autoimmune disease, respectively. Conclusions: In this large, phase II clinical trial of patients with advanced melanoma who progressed on or after ipilimumab, nivolumab demonstrated a safety profile consistent with that of prior clinical trials. ClinicalTrials.gov ID: NCT02156804. © 2019 Elsevier Ltd

Published
2019

35. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)

Author

Nathan, P. Ascierto, P.A. Haanen, J. Espinosa, E. Demidov, L. Garbe, C. Guida, M. Lorigan, P. Chiarion-Sileni, V. Gogas, H. Maio, M. Fierro, M.T. Hoeller, C. Terheyden, P. Gutzmer, R. Guren, T.K. Bafaloukos, D. Rutkowski, P. Plummer, R. Waterston, A. Kaatz, M. Mandala, M. Marquez-Rodas, I. Muñoz-Couselo, E. Dummer, R. Grigoryeva, E. Young, T.C. Schadendorf, D.

Subjects
neoplasms
Abstract

Background: Nivolumab has been widely studied in non-acral cutaneous melanoma; however, limited data are available in other melanoma subtypes. We report outcomes by melanoma subtype in patients who received nivolumab after progression on prior ipilimumab. Patients and methods: CheckMate 172 was a phase II, single-arm, open-label, multicentre study that evaluated nivolumab in patients with advanced melanoma who progressed on or after ipilimumab. Patients received 3 mg/kg of nivolumab, every 2 weeks for up to 2 years. The primary end-point was incidence of grade ≥3, treatment-related select adverse events (AEs). Results: Among 1008 treated patients, we report data on patients with non-acral cutaneous melanoma (n = 723 [71.7%]), ocular melanoma (n = 103 [10.2%]), mucosal melanoma (n = 63 [6.3%]), acral cutaneous melanoma (n = 55 [5.5%]) and other melanoma subtypes (n = 64 [6.3%]). There were no meaningful differences in the incidence of grade ≥3, treatment-related select AEs among melanoma subtypes or compared with the total population. No new safety signals emerged. At a minimum follow-up of 18 months, median overall survival was 25.3 months for non-acral cutaneous melanoma and 25.8 months for acral cutaneous melanoma, with 18-month overall survival rates of 57.5% and 59.0%, respectively. Median overall survival was 12.6 months for ocular melanoma and 11.5 months for mucosal melanoma, with 18-month overall survival rates of 34.8% and 31.5%, respectively. Conclusions: The safety profile of nivolumab after ipilimumab is similar across melanoma subtypes. Compared with non-acral cutaneous melanoma, patients with acral cutaneous melanoma had similar survival outcomes, whereas those with ocular and mucosal melanoma had lower median overall survival. ClinicalTrials.gov ID: : NCT02156804. © 2019 Elsevier Ltd

Published
2019

36. Nivolumab (NIVO) versus ipilimumab (IPI) dans le traitement adjuvant du mélanome réséqué de stade III/IV: résultats d’efficacité à 3 ans et analyse de biomarqueurs issus de l’essai de phase 3 CheckMate 238

Author

Grob, J.-J., primary, Weber, J., additional, Del Vecchio, M., additional, Mandala, M., additional, Gogas, H., additional, Arance, A., additional, Dalle, S., additional, Lance Cowey, C., additional, Schenker, M., additional, Chiarion Sileni, V., additional, Marquez-Rodas, I., additional, Butler, M., additional, Maio, M., additional, Middleton, M., additional, Tang, H., additional, Saci, A., additional, de Pril, V., additional, Lobo, M., additional, Larkin, J., additional, and Ascierto, P.A., additional

Published
2019
Full Text
View/download PDF

37. Combination of intratumoural double-stranded RNA (dsRNA) BO-112 with systemic anti-PD-1 in patients with anti-PD-1 refractory cancer

Author

Marquez-Rodas, I., primary, Longo, F., additional, Aix, S. Ponce, additional, Jove, M., additional, Rubio, B., additional, Blanco, A. Calles, additional, Rodriguez-Ruiz, M.E., additional, Ponz-Sarvise, M., additional, Castañon, E., additional, Gajate, P., additional, Sempere-Ortega, C., additional, Jimenez-Aguilar, E., additional, Lopez-Casas, P., additional, de Miguel, E., additional, Ramos-Medina, R., additional, Calvo, A., additional, Martin, M., additional, Tersago, D., additional, Quintero, M., additional, and Melero, I., additional

Published
2019
Full Text
View/download PDF

39. Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial

Author

Weber, J.S., primary, Del Vecchio, M., additional, Mandala, M., additional, Gogas, H., additional, Arance, A.M., additional, Dalle, S., additional, Cowey, C.L., additional, Schenker, M., additional, Grob, J.J., additional, Chiarion-Sileni, V., additional, Marquez-Rodas, I., additional, Butler, M.O., additional, Maio, M., additional, Middleton, M.R., additional, Tang, T., additional, Saci, A., additional, De Pril, V., additional, Lobo, M., additional, Larkin, J.M.G., additional, and Ascierto, P.A., additional

Published
2019
Full Text
View/download PDF

40. 5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma

Author

Larkin, J.M.G., primary, Chiarion-Sileni, V., additional, Gonzalez, R., additional, Grob, J.J., additional, Rutkowski, P., additional, Lao, C., additional, Cowey, C.L., additional, Schadendorf, D., additional, Wagstaff, J., additional, Dummer, R., additional, Ferrucci, P.F., additional, Smylie, M., additional, Hogg, D., additional, Hill, A., additional, Marquez-Rodas, I., additional, Haanen, J B A G, additional, Rizzo, J., additional, Balogh, A., additional, Hodi, F.S., additional, and Wolchok, J., additional

Published
2019
Full Text
View/download PDF

41. Traitement adjuvant par nivolumab (NIVO) par rapport à l’ipilimumab (IPI) après résection complète d’un mélanome au stade III/IV : résultats actualisés d’un essai de phase III (CheckMate 238)

Author

Weber, J.S., primary, Mandala, M., additional, Del Vecchio, M., additional, Gogas, H., additional, Arance, A.M., additional, Lance Cowey, C., additional, Dalle, S., additional, Schenker, M., additional, Chiarion-Sileni, V., additional, Marquez-Rodas, I., additional, Grob, J.-J., additional, Butler, M., additional, Middleton, M.R., additional, Maio, M., additional, Atkinson, V., additional, Dummer, R., additional, de Pril, V., additional, Qureshi, A., additional, Larkin, J., additional, and Ascierto, P.A., additional

Published
2018
Full Text
View/download PDF

42. Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511)

Author

Lebbé, C., primary, Meyer, N., additional, Mortier, L., additional, Marquez-Rodas, I., additional, Robert, C., additional, Rutkowski, P., additional, Menzies, A.M., additional, Eigentler, T., additional, Ascierto, P.A., additional, Smylie, M., additional, Ajaz, M., additional, Svane, I.-M., additional, Gonzalez, R., additional, Rollin, L., additional, Saci, A., additional, Grigoryeva, E., additional, and Pigozzo, J., additional

Published
2018
Full Text
View/download PDF

43. Intratumoral BO-112, a double-stranded RNA (dsRNA), alone and in combination with systemic anti-PD-1 in solid tumors

Author

Marquez Rodas, I., primary, Longo, F., additional, Rodriguez-Ruiz, M., additional, Calles, A., additional, Pérez-Gracia, J.L., additional, Gomez-Rueda, A., additional, Lopez-Tarruella, S., additional, Ponz-Sarvisé, M., additional, Alvarez, R.M., additional, Soria, A., additional, de-Miguel, E., additional, Gayarre, J., additional, Aznar, M.A., additional, Calvo, A., additional, Lopez-Casas, P.P., additional, Tersago, D., additional, Quintero, M., additional, Martin-Algarra, S., additional, Martín, M., additional, and Melero, I., additional

Published
2018
Full Text
View/download PDF

44. Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)

Author

Hodi, F.S., primary, Chiarion-Sileni, V., additional, Gonzalez, R., additional, Grob, J.J., additional, Rutkowski, P., additional, Cowey, C.L., additional, Lao, C., additional, Schadendorf, D., additional, Wagstaff, J., additional, Dummer, R., additional, Ferrucci, P.F., additional, Smylie, M., additional, Hill, A.G., additional, Hogg, D., additional, Marquez-Rodas, I., additional, Jiang, J., additional, Rizzo, J., additional, Larkin, J., additional, and Wolchok, J., additional

Published
2018
Full Text
View/download PDF

45. SEOM clinical guideline for the management of malignant melanoma (2017)

Author

Universidad de Sevilla. Departamento de Medicina, Universidad de Sevilla. CTS151: Bioquímica médica., Berrocal, A., Arance, A., Castellón, V. E., Cruz Merino, Luis de la, Espinosa, E., Cao, M. G., Larriba, J. L. G., Marquez-Rodas, I., Soria, A., Algarra, S. M., Universidad de Sevilla. Departamento de Medicina, Universidad de Sevilla. CTS151: Bioquímica médica., Berrocal, A., Arance, A., Castellón, V. E., Cruz Merino, Luis de la, Espinosa, E., Cao, M. G., Larriba, J. L. G., Marquez-Rodas, I., Soria, A., and Algarra, S. M.

Abstract

All melanoma suspected patients must be con firmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic mel anoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 containing therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 containing therapy. Up to 10 years follow up is reasonable for melanoma patients with dermatologic examinations and physical exams

Published
2018

46. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma

Author

Weber, J. Mandala, M. Del Vecchio, M. Gogas, H.J. Arance, A.M. Cowey, C.L. Dalle, S. Schenker, M. Chiarion-Sileni, V. Marquez-Rodas, I. Grob, J.-J. Butler, M.O. Middleton, M.R. Maio, M. Atkinson, V. Queirolo, P. Gonzalez, R. Kudchadkar, R.R. Smylie, M. Meyer, N. Mortier, L. Atkins, M.B. Long, G.V. Bhatia, S. Lebbé, C. Rutkowski, P. Yokota, K. Yamazaki, N. Kim, T.M. De Pril, V. Sabater, J. Qureshi, A. Larkin, J. Ascierto, P.A. for the CheckMate 238 Collaborators

Abstract

BACKGROUND: Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In the United States, ipilimumab has also been approved as adjuvant therapy for melanoma on the basis of recurrence- free and overall survival rates that were higher than those with placebo in a phase 3 trial. We wanted to determine the efficacy of nivolumab versus ipilimumab for adjuvant therapy in patients with resected advanced melanoma. METHODS: In this randomized, double-blind, phase 3 trial, we randomly assigned 906 patients (≥15 years of age) who were undergoing complete resection of stage IIIB, IIIC, or IV melanoma to receive an intravenous infusion of either nivolumab at a dose of 3 mg per kilogram of body weight every 2 weeks (453 patients) or ipilimumab at a dose of 10 mg per kilogram every 3 weeks for four doses and then every 12 weeks (453 patients). The patients were treated for a period of up to 1 year or until disease recurrence, a report of unacceptable toxic effects, or withdrawal of consent. The primary end point was recurrence-free survival in the intention-totreat population. RESULTS: At a minimum follow-up of 18 months, the 12-month rate of recurrence-free survival was 70.5% (95% confidence interval [CI], 66.1 to 74.5) in the nivolumab group and 60.8% (95% CI, 56.0 to 65.2) in the ipilimumab group (hazard ratio for disease recurrence or death, 0.65; 97.56% CI, 0.51 to 0.83; P

Published
2017

47. Interferon-Gamma (INFG) as a Biomarker to Guide Immune Checkpoint Blockade (ICB) in Cancer Therapy

Author

Karachaliou, N., Gonzalez Cao, M., Gimenez-Capitan, A., Drozdowskyj, A., Aldeguer, E., Teixido, C., Crespo, G., Molina-Vila, M., Viteri, S., Los Llanos Gil, M., Martin Algarra, S., Perez-Ruiz, E., Marquez-Rodas, I., Rodriguez-Abreu, D., Blanco, R., Puertolas, T., Royo, M. A., and Rosell, R.

Subjects
PD-L1, immune checkpoint blockade (ICB), Interferon-gamma (INFG)
Published
2017

48. Predictive factors of response to immunotherapy-a review from the Spanish Melanoma Group (GEM)

Author

Espinosa, E, Marquez-Rodas, I, Soria, A, Berrocal, A, Manzano, JL, Gonzalez-Cao, M, and Martin-Algarra, S

Subjects
predictive factors, PD-1, melanoma, CTLA-4
Abstract

Immunotherapy has become a key element in the treatment of several tumors, such as lung carcinoma and melanoma. Immunotherapy, unlike classical chemotherapy and targeted drugs, may yield long-term survival, even in patients who stop treatment due to toxicity. This fact has generated considerable excitement and a real shift in the paradigm of cancer treatment. However, only a small subset of patients benefit from immunotherapy. Survival curves show that most patients have progression of the disease in the first months after starting immunotherapy, followed by a slower decrease over the first 3 years, until curves reach a plateau. This early progression suggests the presence of mechanisms for primary resistance. In addition, some patients have tumor relapse after years of response, suggesting that there is also acquired resistance in a small subset of patients. Resistance mechanisms are now being elucidated. PD-L1 expression in tumor and immune cells correlates with higher chances of response, but melanoma patients with PDL1 negative tumors can also respond. Several studies have demonstrated an increased probability of clinical benefit when tumors are infiltrated by CD8 T cells, have a high mutation burden or have an interferon gamma signature. But none of these factors has been implemented in the clinical practice, since more studies confirming their value are needed, as well as the development of standardized techniques.

Published
2017

49. Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM)

Author

Gonzalez-Cao, M, Berrocal, A, Puig, S, Karachaliou, N, De Matos-Arruda, L, Seoane, J, Escors, D, Alvarez, C, Vaque, JP, Prat, A, Wellbrock, C, Arozarena, I, Marquez-Rodas, I, Espinosa, E, Molina, MA, Puertolas, T, Juan-Otero, M, Malagrida, R, Jantus-Lewintre, E, Soriano, V, Arance, A, Manzano, JL, Lorigan, P, Gajewski, TF, Rosell, R, and Martin-Algarra, S

Subjects
medicine.medical_specialty, Medical education, Research groups, business.industry, translational, Translational research, General Medicine, meeting, Meeting Report, Spanish, Preclinical data, Basic research, Ophthalmology, medicine, business, Melanoma
Abstract

The II melanoma translational meeting of the Spanish Melanoma Group (GEM) was held in Barcelona, Spain, at the Hospital Universitari Quiron-Dexeus on November 3 rd , 2016. The conference featured leaders in the fields of oncology, immunology and dermatology, all working at both national and international levels on basic research with direct applications to the clinical setting. The objective was to present cutting edge research on melanoma, mainly from Spanish research groups, but also from some international groups, with the aim of generating a network for future national and international collaborations. During a single day, fifteen speakers, seven biologists and eight clinicians, with a special focus on translational research, outlined the main findings of their ongoing studies. The moderators in every session were recognized GEM oncologists who guided discussion from the clinical point of view regarding the preclinical data presented. Herein, we summarize the main topics discussed during the meeting.

Published
2017

50. Nivolumab (NIVO) vs ipilimumab (IPI) en traitement adjuvant du mélanome de stade III/IV opéré : résultats de survie sans récidive (SSR) et de survie globale (SG) à 4 ans de l’essai CheckMate 238

Author

Weber, J., Del Vecchio, M., Mandalá, M., Gogas, H., Arance, A.M., Dalle, S., Cowey, C.L., Schenker, M., Grob, J.-J., Chiarion-Sileni, V., Márquez-Rodas, I., Butler, M.O., Maio, M., Middleton, M.R., Del La Cruz-Merino, L., Lobo, M., De Pril, V., Larkin, J., and Ascierto, P.A.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results